Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of Sunday, August 23, 2026.
Forward PE Ratio (N/A) = Close Price ($116.57) / Consensus Forward EPS ($-5.70)
FORWARD PE RATIO
N/A
BioNTech SE
Market Cap
$29.28B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| BioNTech SE (BNTX) | $29.28B | N/A |
| Medline Inc. (MDLN)vs › | $28.97B | 22.71 |
| Mettler-Toledo International Inc. (MTD)vs › | $28.19B | 29.48 |
| Waters Corporation (WAT)vs › | $30.72B | 28.18 |
| Labcorp Holdings Inc. (LH)vs › | $27.58B | 18.35 |
| Quest Diagnostics Incorporated (DGX)vs › | $26.97B | 21.84 |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $31.61B | 36.30 |
| Biogen Inc. (BIIB)vs › | $32.03B | 17.40 |
| Centene Corp. (CNC)vs › | $32.12B | 13.54 |
| Zoetis Inc. (ZTS)vs › | $32.59B | 12.35 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus next-FY EPS
At today's $116.57 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-5.70 | $-6.15 – $-5.25 | 9 | n/m |
| 2027-12-31 | $-5.68 | $-6.85 – $-4.52 | 9 | n/m |
| 2028-12-31 | $-4.22 | $-11.36 – $1.23 | 13 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
